Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel

BACKGROUND: In recent years treatment options for advanced pancreatic cancer have markedly improved, and a combination regimen of gemcitabine and nab-paclitaxel is now considered standard of care in Sweden and elsewhere. Nevertheless, a majority of patients do not respond to treatment. In order to g...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Cancer
Egile Nagusiak: Blomstrand, Hakon, Green, Henrik, Fredrikson, Mats, Gränsmark, Emma, Björnsson, Bergthor, Elander, Nils O.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530950/
https://ncbi.nlm.nih.gov/pubmed/33008332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07426-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak